Edesa Biotech, Inc. (EDSA) Stock Price & Analysis
Edesa Biotech, Inc. (EDSA) fell 8.01% to USD 4.94 as of June 10, 2026 at 03:07 UTC, according to Nexqual real-time market data.
EDSA last closed at USD 5.37; the session ranged USD 4.56–5.59 on volume of 292,899 shares. Market capitalization is $43.93M, with a 52-week range of USD 0.72–20.32 (NCM). Source: Nexqual, June 10, 2026 at 03:07 UTC.
Key Statistics (as of June 10, 2026 at 03:07 UTC)
| Price | USD 4.94 |
|---|---|
| Change | ▼ 8.01% (down) |
| Previous Close | USD 5.37 |
| Open | USD 5.33 |
| Day Range | USD 4.56 – 5.59 |
| 52-Week Range | USD 0.72 – 20.32 |
| Volume | 292,899 shares |
| Market Cap | $43.93M |
| Exchange | NCM |
Technical Analysis (EDSA)
Nexqual's technical model rates EDSA "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:07 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.54 (neutral) |
| vs SMA50 | Below (USD 9.45) |
| MACD | -1.57 (negative) |
Analyst Ratings (EDSA)
Wall Street analysts rate EDSA "None" based on 2 analysts, with a mean price target of USD 14 (range USD 9–19), per Nexqual as of June 10, 2026 at 03:07 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 14 |
| High Target | USD 19 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (EDSA)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.49 vs est -0.26 ▼ miss |
| 2025-12-31 | USD -0.28 vs est -0.45 ▲ beat |
| 2025-09-30 | USD -0.32 vs est -0.27 ▼ miss |
| 2025-06-30 | USD -0.25 vs est -0.26 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Financials & Fundamentals (EDSA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -81.16% |
| Current Ratio | 4.76 |
| Total Cash | $10.00M |
| Total Debt | $0 |
| Free Cash Flow | $-3.96M |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Financial Health Score (EDSA)
Nexqual rates Edesa Biotech, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:07 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $10M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$8M |
| Efficiency | Critical — ROE -81%, ROA -47.7% |
Ownership (EDSA)
| Insider Ownership | +18.87% |
|---|---|
| Institutional Ownership | +36.48% |
| Shares Outstanding | 8.89M |
| Float | 5.54M |
| Short % of Float | +2.91% |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Leadership (EDSA)
Edesa Biotech, Inc. is led by Pardeep Nijhawan FRCPC (age 54), CEO, Company Secretary & Director, per Nexqual as of June 10, 2026 at 03:07 UTC.
| CEO, Company Secretary & Director | Pardeep Nijhawan FRCPC (age 54) |
|---|---|
| President | Michael J. Brooks (age 46) |
| Chief Financial Officer | Peter John Weiler M.B.A, M.Sc. (age 56) |
Major Backers & Investors (EDSA)
Notable institutional backers of Edesa Biotech, Inc. include Velan Capital Investment Management LP, Rubric Capital Management LP, Perceptive Advisors Llc, according to Nexqual as of June 10, 2026 at 03:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Velan Capital Investment Management LP | 9.31% |
| Rubric Capital Management LP | 7.73% |
| Perceptive Advisors Llc | 6.33% |
| Jane Street Group, LLC | 1.3% |
| Fidelity | 0.75% |
| Commonwealth Equity Services, LLC | 0.39% |
| Scientech Research LLC | 0.34% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.37% |
| Geode Capital | 0.87% |
| State Street | 0.43% |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
From Edesa Biotech, Inc.'s Latest SEC 10-K Filing (filed 2025-12-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases.
- It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
- The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B.
- It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CRVS | Corvus Pharmaceuticals, Inc. | USD 11.17 | ▲ 0.45% |
| SNOA | Sonoma Pharmaceuticals, Inc. | USD 1.11 | ▼ 2.63% |
| IMRN | Immuron Limited | USD 1.19 | ▼ 4.8% |
| ADTX | Aditxt, Inc. | USD 0.03 | ▼ 53.39% |
| ATHE | Alterity Therapeutics Limited | USD 4.29 | ▲ 10% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:07 UTC. This page is informational and not investment advice.